Given that PARPs’ or PARG activities have been demonstrated to interfere with nucleocytoplasmic shuttling of FUS in the cytoplasm upon genotoxic stress [101,119], these data may extend the range of applications of PARPs or PARG inhibitors from cancer to neurodegenerative diseases [120]. The gene discussed is PARG; the disease is neurodegenerative disease.